Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Overview of Immutep Ltd
Immutep Ltd is a globally active biotechnology company committed to advancing immunotherapy for both cancer and autoimmune diseases. Leveraging its expertise in immuno-oncology and innovative LAG-3 technology, the company has positioned itself as a specialized entity in personalized bio-therapeutic products. With dual listings on the Australian Stock Exchange and Nasdaq, Immutep demonstrates a robust international presence and a solid foundation in research and development.
Core Technology and Therapeutic Approach
The hallmark of Immutep’s approach is its focus on the LAG-3 immune control mechanism, a critical regulator of the T cell immune response. By modulating this pathway, Immutep aims to enhance the body’s natural ability to fight cancer and potentially address autoimmune conditions. This technology underpins the company’s strategic pipeline and sets a high standard for clinical precision and targeted therapy development.
Product Pipeline and Clinical Development
Immutep’s product portfolio is centered around its most advanced candidate, IMP321, which functions as a T cell immunostimulatory factor. This therapy is designed for integration into cancer chemoimmunotherapy protocols and has achieved significant clinical milestones in early phase trials. In addition to IMP321, the company is developing IMP701, a blocking anti-LAG-3 antibody candidate in early clinical evaluation, and CVac, a personalized immunocellular strategy under investigation for epithelial cancers. These development efforts illustrate a diverse and forward-looking approach that integrates both innovation and strategic collaboration.
Global Operations and Strategic Collaborations
Operating primarily from Australia, Immutep extends its influence across global markets, supported by strong regulatory compliance and research proficiency. Strategic partnerships with large pharmaceutical firms reinforce its pipeline development, enabling access to advanced clinical platforms and shared expertise. The company’s qualification for significant research tax incentives in both Europe and Australia underscores its commitment to high-caliber R&D and validates the commercial and scientific merits of its initiatives.
Industry Position and Business Model
Within the competitive landscape of biotechnology, Immutep differentiates itself by combining deep scientific expertise with a focused therapeutic strategy. Its business model hinges on collaborative partnerships, clinical innovation, and a targeted approach to harnessing LAG-3 mediated immune modulation. Investors and industry observers appreciate the rigorous clinical frameworks employed by the company, which underpin its potential to offer novel therapeutic modalities in the area of cancer treatment and beyond.
Research and Development Excellence
Immutep’s strategic emphasis on research and development is reflected in its participation in international R&D incentive programs. These initiatives not only provide substantial financial support for its clinical trials but also affirm the company’s adherence to high industry standards and scientific integrity. This relentless focus on innovation is at the core of Immutep’s operational ethos, ensuring that its immunotherapeutic solutions are developed in a rigorous and transparent environment.
Conclusion
In summary, Immutep Ltd stands as a key player in the biotechnology industry, with a specific focus on immunotherapy modalities for cancer and autoimmune diseases. Its reliance on advanced LAG-3 technology, comprehensive product pipeline, and robust global partnerships collectively fortify its standing in the competitive landscape. The company’s commitment to R&D excellence and transparent clinical strategies provides a rich source of insight for those seeking to understand a pioneering approach in modern biotechnology.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced new biomarker data from its Phase IIb AIPAC trial at the ESMO Breast Cancer Congress 2022, occurring from May 3-5, 2022, in Berlin, Germany. The trial assessed eftilagimod alpha combined with paclitaxel in 227 HER2-negative/HR positive metastatic breast cancer patients. New multivariate analysis results will be presented by Prof. Dr. Frederik Marmé on May 4, 2022. For further details, visit Immutep's website.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of patent no. 7030750 by the Japanese Patent Office for antibody molecules targeting LAG-3, crucial for cancer treatment. This divisional patent follows a previous grant in 2019, with corresponding patents in territories like Australia, China, Europe, and the U.S. The patent, co-owned with Novartis AG, will expire on March 13, 2035. LAG525, a humanized form of IMP701, is being evaluated by Novartis in clinical trials for cancer, with Immutep set to receive milestone payments and royalties upon commercialization.
Immutep Limited (NASDAQ: IMMP) announced that it received positive feedback from the FDA regarding its lead product, eftilagimod alpha (efti), for the treatment of metastatic breast cancer (MBC). The FDA supports advancing efti into a new registrational trial, AIPAC-003, which will optimize patient selection based on completed phase IIb AIPAC trial data. This follows earlier feedback from the EMA. The upcoming trial aims to solidify the best design for efti, which targets patients who are unlikely to benefit from conventional therapies.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its participation in notable investor conferences, including the 42nd Annual Cowen Health Care Conference from March 7-9, 2022, where CEO Marc Voigt will present on March 8 at 9:10 am EST. A live webcast will be available. Additionally, Immutep will engage in a fireside chat at the Maxim Growth Conference from March 28-30, 2022, set for March 28 at 11:00 am EDT. Immutep focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases.
Immutep (ASX: IMM; NASDAQ: IMMP) will present new data from its phase II TACTI-002 trial at the European Lung Cancer Congress (ELCC) 2022 in Prague and virtually from March 30 to April 2, 2022. The study evaluates eftilagimod alpha combined with KEYTRUDA® in patients with PD-L1 unselected, refractory metastatic non-small cell lung cancer (NSCLC). The poster presentation is scheduled for April 1, 2022, at 12:00 noon CEST by Dr. Matthew G. Krebs. Immutep aims to advance its LAG-3 related immunotherapeutic developments.
Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent by the Australian Patent Office for its lead immunotherapy candidate, eftilagimod alpha (efti or IMP321). This patent, protecting combined preparations for treating cancer, follows similar grants in Europe, the U.S., and China. The claims cover specific combinations of efti with various anti-PD-1/PD-L1 antibodies, expiring on January 8, 2036. CEO Marc Voigt highlighted the importance of this patent in the context of significant interest in the LAG-3 mechanism following Phase III clinical data publication.
Immutep (ASX: IMM; NASDAQ: IMMP) has announced participation in two key investor conferences in February 2022. CEO Marc Voigt will present at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, followed by a Q&A session on February 18 at 3:40 PM ET. Additionally, Immutep will be at the 2022 BIO CEO & Investor Conference from February 14-17. The company's focus is on developing immunotherapy treatments for cancer and autoimmune diseases, primarily through its lead candidate, eftilagimod alpha.
Immutep Limited (NASDAQ: IMMP) reported significant advancements in its clinical trials for cancer therapies, particularly its lead product, eftilagimod alpha (efti). The Phase IIb AIPAC trial demonstrated a notable overall survival benefit, with a +7.5 month increase for patients under 65 and +19.6 months for those with low monocytes. The company is preparing for a Phase III trial and has initiated patient recruitment for TACTI-003. Financially, cash on hand is $99.66 million, projected to fund operations until December 2023.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a Manufacturing Service Agreement with Northway Biotech to produce its preclinical candidate, IMP761, aimed at autoimmune diseases. Northway will develop a GMP-compliant manufacturing process for IMP761 at its facility in Lithuania, with plans for clinical trials post-preclinical development. IMP761 targets autoimmune memory T cells expressing LAG-3, potentially addressing the root causes of autoimmune diseases. Preclinical results from 2019 indicated its ability to reduce T cell infiltration.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the treatment of the first five patients in its INSIGHT-003 study, which evaluates a triple combination therapy featuring eftilagimod alpha (efti) alongside chemotherapy and anti-PD-1 therapy. The study, led by Prof. Dr. Salah-Eddin Al-Batran, has reported no new safety signals and is progressing well, with patient recruitment on track. Up to 20 patients with solid tumors will be recruited, assessing safety, tolerability, and initial efficacy, with further results anticipated in 2022.
FAQ
What is the current stock price of Immutep (IMMP)?
What is the market cap of Immutep (IMMP)?
What is the core focus of Immutep Ltd?
How does Immutep utilize LAG-3 technology in its treatments?
What are the key products in Immutep’s development pipeline?
In what ways does Immutep engage in global operations?
How do Immutep’s strategic partnerships influence its business model?
What role do research tax incentives play in Immutep’s operations?
How does Immutep maintain its expertise and trustworthiness in the biotech industry?
